CSIMarket Company Name, Ticker, Customers, else..
 
Endonovo Therapeutics Inc   (ENDV)
Other Ticker:  
 
 
Price: $0.0001 $0.00 -50.000%
Day's High: $0.0002 Week Perf: -50 %
Day's Low: $ 0.00 30 Day Perf: -50 %
Volume (M): 1,680 52 Wk High: $ 0.01
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 1,351
 Employees 10
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Endonovo Therapeutics Inc
Endonovo Therapeutics Inc. is a biotechnology company based in the United States. The company focuses on the development and commercialization of non-invasive electroceutical therapies for the treatment of various inflammatory and autoimmune diseases. Their flagship product is the SofPulse device, which delivers pulsed electromagnetic fields to target areas of the body and stimulate the body's natural regenerative processes. The company aims to provide safe and effective alternative treatment options for conditions such as inflammation, pain, and tissue damage. Endonovo Therapeutics Inc. has conducted clinical trials and is working towards obtaining regulatory approvals for their products.


   Company Address: 6320 Canoga Avenue Woodland Hills 91367 CA
   Company Phone Number: 489-4774   Stock Exchange / Ticker: ENDV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ARTH      % 
BSTG        14.1% 
CTCX   -12.54%    
MARZ        1.44% 
TSOI   -33.33%    
VYCO        52.43% 
• View Complete Report
   



Endonovo Therapeutics Inc

Extremely demanding reporting season for the Endonovo Therapeutics Inc in the July to September 30 2023 financial time-frame



Endonovo Therapeutics Inc, a medical equipment and supplies company, recently reported its financial results for the July to September 2023 time-frame. The results show a balanced book of $0.00 per share, which is the same as the previous year. However, this is an improvement from the prior reporting season where the company faced a loss of $0.01 per share. Despite a significant fall in revenue to $0.00 million, the company's stock has experienced a notable surge in the past week. This article aims to outline the facts and interpret the implications of these financial results.
Financial Results Overview:
Endonovo Therapeutics Inc's financial results for the July to September 2023 time-frame indicate mixed performance. While the company achieved a balanced book, showing stability and maintaining its previous year's position, the revenue fell sharply to zero. This decline is in contrast to the overall Medical Equipment & Supplies industry, which recorded revenue gains during the period.
Endonovo Therapeutics Inc

ENDV's Revenue Surges, but Profitability Remains Elusive for Endonovo Therapeutics Inc

Endonovo Therapeutics Inc, a medical equipment and supplies company, has recently announced a very solid revenue improvement year on year to $0.05 million in the fiscal interval ending June 30, 2023. However, the company suffered a loss of $-0.01 during this period.
This revenue improvement is particularly notable when compared to its peers in the Medical Equipment & Supplies industry, who only saw an overall 3.96% business improvement during the same time frame. This positive performance indicates that Endonovo Therapeutics Inc is outperforming its industry competitors in terms of revenue growth.
Endonovo Therapeutics Inc

Endonovo Therapeutics Inc. Strikes Gold with Soaring Profits in Q1 2023, Anchors Impressive Revenue Jump to $0.09 Million!

Endonovo Therapeutics Inc. has reported an impressive revenue growth for the fiscal period ending on March 31, 2023, with a year-on-year increase to $0.09 million. The company has also managed to turn around its earnings, with the display of EPS at $0.03, compared to the previous year's income per share, which was at $-0.05 per share. However, there was a decline in revenue by -27.929% from $0.12 million.
The company has booked a net income of $7.231 million in the first quarter of 2023, an improvement compared to the comparable reporting season a year ago, which had a net deficit of $-2.413 million. This marks the company's positive financial turnaround and highlights the effectiveness of their strategic financial plan.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com